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Objective: To determine the prevalence of Diabetic Nephropathy (DN) in patients with type 2 Diabetes
Mellitus (T2DM) with over 5 years of evolution in rural communities of Guanajuato, Mexico, and eval-
uate the effects of an ARB treatment over 6 months in patients with DN.
Materials and methods: Patients of both sexes, 38–86 years, T2DM over 5 years of evolution and diag-
nosed with arterial hypertension (HT) after T2DM incidence. Monthly determination of microalbuminuria
(MA), lipids, glucose, serum creatinine, and glycated hemoglobin (HbA1c). Estimated glomerular ﬁltra-
tion rate (eGFR) by theModiﬁcation of Diet in Renal Disease (MDRD) formula. A dose of 80mg of Telmisartan
was administered daily over 6 months.
Results: The total adult population of two rural communities (3609 subjects) was studied, 335 subjects
had T2DM, among them 80 (with a prevalence of 24%) had DN and HT. Sixty-seven patients received
Telmisartan, and showed signiﬁcant improvement in all parameters studied.
Conclusions: A higher prevalence of DN than that reported in the Mexican National Health Survey
(ENSANUT) was found. Further research is required in a larger population sample in order to conﬁrm
the results of Telmisartan treatment.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
According to theMexican National Health Survey ENSANUT, 2006,
the national prevalence of Type 2 Diabetes Mellitus (T2DM) is 7%,
being higher in women (7.3%) than in men (6.5%). The state of Gua-
najuato is below the national average, with a prevalence of 5.6% in
adults aged 20 years or older, the prevalence is similarly higher in
women (6.3%) than in men (4.7%) [1].
DN prevalence varies between 5% and 30% in patients with T2DM
and MA is present in 40% of the subjects after 10 years of evolu-
tion. The risk of a progressive increase in albumin excretion to overt
proteinuria within 6–14 years was 60–80% [2–6].
DN is the most common cause of end stage renal disease (ESRD)
[2]. The MA in subjects with diabetes mellitus (DM) is a major
independent risk factor for cardiovascular events [7–9]. The inci-
dence of ESRD in DN patients is 60% in Mexico. More than one in
two ESRD patients in the State of Jalisco (Mexico) and the State of
Morelos (Mexico) are reported to have diabetes. In Morelos, rates
of diabetes in subjects 45–75 years and older are up to 1786 per
million population according to the United States Renal Data System
2011 Annual Data Report [10].
The renin–angiotensin system plays a predominant role in the
evolution of renal disease, not only by inducing changes in arteri-
al pressure (BP) and glomerular hemodynamics [11], but also by
increasing oxidative stress and promoting expression of pro-
inﬂammatory genes and pro-ﬁbrotic factors in mesangial cells and
vascular smooth muscle [12], additionally, angiotensin II pro-
motes mesangial cell and vascular smooth muscle proliferation,
thus contributing to the enlargement of the arteriolar wall. Acti-
vated inﬂammatory cells, especially T cells, synthesize angiotensin,
thereby reinforcing intrarenal angiotensin production [13].
Prospective controlled clinical studies show that angiotensin con-
verter enzyme inhibitors (ACE), as well as angiotensin receptor
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blockers (ARBs), are able to stop or slow the progression of DN
[14].
In subjects with T2DM, the eGFR decreases by approximately
6 mL/min per year [15], however, it has been observed that the ad-
dition of ACE inhibitors or ARBs to patients’ treatment regimens,
while not hypertensive, achieved a reduction in the rate of pro-
gression of the fall in eGFR, thereby stabilizing renal function for a
prolonged period [14].
Moreover, metabolic control reduces catabolism and improves
nutritional status, decreases or delays the onset of DN, and reduces
glomerular hyperﬁltration [16,17].
Given the signiﬁcant annual increase in the number of pa-
tients with terminal DN, continued research aimed at early detection
of DN and its treatment is required. Therefore, the present study
was conducted in two rural communities in the state of Gua-
najuato in order to determine the prevalence of DN in T2DM patients
with at least 5 years of disease evolution, and to study the possi-
ble renoprotective effect of an ARB (Telmisartan) at a dose of 80mg/
24 hr for a 6 month period.
Materials and methods
A quasi-experimental study was performed. To assess the prev-
alence of DNwe included and evaluated all adult people of the rural
communities of San Juan Jaripeo (N = 1835) and Colonia Morelos
(N = 1774), in the State of Guanajuato, Mexico. All subjects had Social
Security coverage, aﬃliated as follows: Mexican Health Institutes
ISSSTE 223 (6%), IMSS (8%) and Popular Health Insurance (86%). All
patients, independently of their medical aﬃliation, were treated in
the Medical Primary Health Care Centers, during the period of No-
vember 2010 to April 2011. All 3609 patients of both sexes who
had been diagnosed with T2DM over at least 5 years were in-
cluded, they were under oral hypoglycemic agents or insulin, and
were later diagnosed with HT which they controlled with various
antihypertensive medications. Patients had no evidence of clinical
nephropathy, or any other chronic disease, or general or local in-
fectious disease. Their body mass index (BMI) was greater than 18.
One of the objectives in this study was to evaluate the effect of
ARB treatment in patients with DM, therefore, those patients that
required more than one drug to control hypertension were not in-
cluded. Patients with less than 85% adherence to drug treatment,
and those who did not attend two consecutive appointments were
withdrawn from the study.
The DM treatment schedule remained unchanged, but the anti-
hypertensive treatment was replaced by Telmisartan.
The study was approved by the Research Ethics Committee of
Quetzalcoatl University, Mexico, according to the guidelines of the
Ley General de Salud en Materia de Investigación [18]. All patients
signed a letter of informed consent.
A clinical history was undertaken at the beginning of the study
and the weight, height, BMI and BP at rest (performed in two read-
ings within 15 minutes) were obtained, at the beginning, and after
3 and 6 months of the trial.
Glucose, creatinine, cholesterol, HDL, LDL (Ortho Clinical Diag-
nostic IVD), serum, and HbA1c (Hemoglobin 1AC Systems DCA) levels
were determined after 12 hours of fasting. Quantitative MA (Ortho-
Clinical-diagnostic IVI) wasmeasured using the 411 COBA apparatus.
Monthly urinalysis and quantitative determination of MA was per-
formed using Combur Test ROCHE strips, MA was reported as mg/L
according to Kumar et al. [19]. Similarly capillary glucose was per-
formed using Combur Test ROCHE strips. The eGFR was calculated
using the abbreviated MDRD formula [20], CKD was classiﬁed ac-
cording to the guidelines of the KDOQI (Kidney Disease Outcomes
Quality Initiative) Clinical Practice [21].
All patients received 80 mg of Telmisartan daily.
Statistical analysis
Data were tested for normality, descriptive statistics (mea-
sures of central tendency and distribution), frequency tables and
percentages, inferential statistics, Friedman ANOVA for repeatedmea-
sures were performed. The STATISTICA version 7 statistical package
was used. Intention to treat analysis was not performed because all
selected patients were treated with telmisartan, therefore no control
group nor randomization were carried out.
Results
Out of a total of 3609 individuals, 335 had T2DM, 80 patients
(23.8%) had DN and HT. Thirteen patients were removed, because
they were lost to follow-up because of change of residency after the
ﬁrst appointment, leaving 67 patients for analysis (11 men, and 56
women), with an average age of 62 years (range of 38–88 years).
Table 1 shows the signiﬁcant changes found in BP in both men
andwomen after 6 months of Telmisartan treatment. Serum glucose
decreased inmen andwomen after treatment, evenwhen the HbA1c
decreased signiﬁcantly only in women. The serum creatinine and
eGFR values by the MDRD (65.9 ± 22.2) and the CKD-EPI (64.1 ± 19)
formulas (t = 0.510, p = 0.21) showed a similar decrement in both
sexes at the end of treatment. However, the values of MA de-
creased signiﬁcantly only in women after treatment.
Fig. 1 shows the changes in the stratiﬁcation of chronic renal
disease after 6 months of treatment with Telmisartan. Twenty-
seven patients were treatedwith Telmisartan in stages 3 and 4 before
treatment, and after treatment there were only 19 patients. A total
of 40 patients were in steps 1 and 2 before treatment, and in-
creased to 44 after treatment. Four patients showed normal eGFR
after treatment with Telmisartan.
Discussion
In this study population the prevalence of T2DM was found to
be 9.28%, which is similar to that reported in the Mexican Encuesta
Nacional de Salud y Nutrición 2012 [1].
The prevalence of DN in patients studied was 23.8%, lower than
the prevalence of DN at 38.5–39.6% reported by Plantinga LC [22].
It is possible that the difference in DN prevalence is partially due
to the fact that the majority of women in these communities are
housewives entitled to the ‘Oportunidades’ (Opportunities) program,
run by theMinistry of Health, and therefore regularly attendmedical
appointments [23,24].
The INNOVATION study shows the effect on the progression of
DN using different doses of Telmisartan [11]. In this regard, the ad-
ministration of 80 mg/day of Telmisartan showed that 16.7% of
patients suffered a progression of renal damage, while 22.6% of pa-
tients receiving 40 mg/day of Telmisartan showed progression of
DN, which is much lower than the ﬁgure observed (49.9%) in pa-
tients that received placebo.
This same study (INNOVATION) referred MA to 21.2% and 12.8%
of the patients at the dose of 80mg/day and 40mg/day respectively.
Similar to the INNOVATION study results we found, in our study,
that a dose of Telmisartan 80 mg/day administered for 6 months
resulted in a signiﬁcant decrease in the presence of MA in women
(34.0 ± 13.5 mg/L to 20.6 ± 15.1 mg/L, p < 0.00000), and an in-
crease in eGFR in both men and women (63.4 ± 20.2 mL/min to
72.0 ± 19.5mg/mL, p < 0.00000). We also used the CKD-EPI formula,
founding no differences with the abbreviated MDRD formula.
Several studies [25–37] have shown that the administration of
Telmisartan in patients with T2DM and diabetic nephropathy, with
or without hypertension, signiﬁcantly improves glucose tolerance
and insulin resistance. In this regard, we found a signiﬁcant
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improvement in the patient’s metabolic control, with a signiﬁcant
decrease in serum glucose levels (196 ± 108.0 mg/dL to
140.6 ± 44.2 mg/dL, p < 0.00001), and in the HbA1c (8.1 ± 2.1 ± 1.1%
to 7%, p < 0.001), as well as the concentration of total cholesterol
(217.2 ± 64.5 to 190.7 ± 38.8 p < 0.0001). Masaki and colleagues iden-
tiﬁed that the effect of Telmisartan on insulin resistance is seen only
in overweight and obese patients [25], which may explain our ﬁnd-
ings because the women in this study were more overweight or
obese than men.
The study was conducted in rural municipalities in the state of
Guanajuato, where the female population is greater than the male
population. Almost all women in these communities are house-
wives, and aremostly the beneﬁciaries of the Opportunities program,
and therefore regularly attend medical appointments [23,24]. Men
are mainly agricultural workers, or have migrated to the United
States, which means that they cannot attend appointments [24].
Moreover, other factors must also be considered that may cause poor
adherence to medical treatment such as the use of medicinal plants,
low education levels, and lack of information [38].
Finally, wemust state that there are some limitations to our study;
although measuring urinary creatinine allows to correct potential
variable concentration during the day, we did not measured urinary
creatinine and therefore we did nor calculate the ACR. Another lim-
itation is that we cannot infer causality because this is not a
randomized clinical trial.
Conclusions
The prevalence of T2DM was 9.28% and for DN was 23.8%. We
found improvement of systolic blood pressure, urinary albumin ex-
cretion, eGFR, and themetabolic control after Telmisartan treatment,
in overweight and/or obese T2DM patients. Telmisartan effect should
be evaluated in T2DM with normal weight.
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Table 1
Clinical characteristics of the studied population
Start Three
months
Six
months
x2 p
Mean ± SD Mean ± SD Mean ± SD
Age (years)
Men 69.3 ± 11 69.3 ± 11 69.3 ± 11
Women 61.5 ± 12 61.5 ± 12 61.5 ± 12
BMI (kg/m2)
Men 28.13 ± 2.9 28.10 ± 2.9 28.03 ± 2.9 4 <0.1
Women 29.13 ± 6.5 29.15 ± 7.2 29.21 ± 7.0 4 <0.1
SPB (mmHg)
Men 165 ± 21.6 139.0 ± 15.0 128 ± 7.3 13.27 <0.001
Women 144.6 ± 21.9 127.3 ± 12.7 124.3 ± 8.8 38.4 <0.00000
DBP (mmHg)
Men 92 ± 1.9 83.0 ± 7 84 ± 4.9 3.75 <0.1
Women 84.3 ± 10.8 80.5 ± 6.8 80.1 ± 6.5 2.9 <0.2
HbA1c (%)
Men 8.7 ± 1.7 7.8 ± 1.3 7.7 ± 1.1 3.8 <0.1
Women 8.1 ± 2.1 7.3 ± 1.5 7 ± 1.1 20.9 <0.000
Serum glucose (mmol/L)
Men 12.73 ± 6.13 9.13 ± 2.52 7.94 ± 2.1 6.83 <0.03
Women 10.8 ± 5.99 8.69 ± 3.31 7.8 ± 2.45 26.4 <0.00000
Cholesterol (mmol/L)
Men 5.15 ± 1.78 4.99 ± 1.21 5.5 ± 1.45 0.19 0.9
Women 5.65 ± 1.68 5.23 ± 1.18 4.96 ± 1.01 18.59 <0.0000
Creatinine serum (mmol/L)
Men 98.1 ± 26.5 99.01 ± 26.5 84.8 ± 17.2 13.8 <0.000
Women 91 ± 26.5 87.5 ± 26.5 80.4 ± 17.2 46.5 <0.00000
eGFR (mL/min/1.73m2)
Men 78.7 ± 28.0 78.6 ± 27.9 88.1 ± 23.22 20.60 <0.0000
Women 63.4 ± 20.2 63.3 ± 20.2 72.0 ± 19.5 78.5 <0.00000
Micro albuminuria (mg/L)
Men 31 ± 14.9 31.4 ± 15.1 24.9 ± 21.3 2.36 0. 3
Women 34.0 ± 13.5 29.1 ± 15.2 20.6 ± 15.1 53.37 <0.00000
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; eGFR, glomerular ﬁltration estimated by MDRD formula.
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Figure 1. Comparison of the number of stratiﬁcation cases, according to the K/DOQI
at the beginning and the end of the study.
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